EGFR and glioblastoma: Moreover, recent research has revealed that EGFR-targeted inhibitors in glioblastoma cell lines increase mitochondrial translocation of both EGFR and EGFRvIII, causing mitochondrial accumulation of these receptors and contributing to tumor drug resistance, thus providing evidence for a connection between the mitochondrial EGFR pathway and apoptosis.